Vol 89, No 9 (2018)
Research paper
Published online: 2018-09-28
Does endocan level increase in women with polycystic ovary syndrome? A case — control study
Abstract
Objectives: To evaluate endocan levels of patients with polycystic ovary syndrome (PCOS) in comparison to healthy women.
Material and methods: A cross-sectional case-control study on 88 patients with PCOS (mean age, 22.06 ± 4.24 years; body mass index [BMI], 23.9 ± 4.74 kg/m2) and 87 age- and BMI-matched healthy women (mean age, 23.71 ± 4.42 years; BMI, 22.15 ± 3.03 kg/m2).
Results: Serum endocan level was significantly higher in PCOS group than control group (540.9 ± 280.3 pg/mL vs. 355.5 ± 233.5 pg/mL, respectively; p < 0.001). The presence of polycystic ovary finding on ultrasonography or oligomenorhea did not produce significant effect on serum endocan levels (p > 0.05). In PCOS group, endocan level was negatively correlated with BMI and C-reactive protein level, and positively correlated with high density lipoprotein level (p < 0.05).
Conclusions: Blood endocan level is increased in PCOS. Further studies are needed to evaluate the clinical value of blood endocan level as a marker for the risk of cardiovascular and metabolic diseases in patients with PCOS.
Keywords: endocanpolycystic ovary syndromeinflammationcase-control
References
- Carmina E, Orio F, Palomba S, et al. Endothelial Dysfunction in PCOS: Role of Obesity and Adipose Hormones. The American Journal of Medicine. 2006; 119(4): 356.e1–356.e6.
- Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care. 1999; 22(1): 141–146.
- Legro RS, Kunselman AR, Dodson WC, et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab. 1999; 84(1): 165–169.
- Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. 2001; 103(10): 1410–1415.
- Diamanti-Kandarakis E, Alexandraki K, Protogerou A, et al. Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol. 2005; 152(5): 749–756.
- Diamanti-Kandarakis E, Spina G, Kouli C, et al. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab. 2001; 86(10): 4666–4673.
- Kelly CC, Lyall H, Petrie JR, et al. Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 2001; 86(6): 2453–2455.
- Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod. 2006; 21(6): 1426–1431.
- Shimokawa H. Primary endothelial dysfunction: atherosclerosis. J Mol Cell Cardiol. 1999; 31(1): 23–37.
- Ross R. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999; 340(2): 115–126.
- Aparci M, Isilak Z, Uz O, et al. Endocan and endothelial dysfunction. Angiology. 2015; 66(5): 488–489.
- Mihajlovic DM, Lendak DF, Brkic SV, et al. Endocan is useful biomarker of survival and severity in sepsis. Microvasc Res. 2014; 93: 92–97.
- Kao YH, Chiu WC, Hsu MI, et al. Endothelial progenitor cell dysfunction in polycystic ovary syndrome: implications fort he genesis of cardiovascular diseases. Int J Fert Steril. 2013; 6: 208–213.
- Bicer M, Guler A, Unal Kocabas G, et al. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res. 2017; 42(2): 145–153.
- Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group, Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004; 19(1): 41–47.
- FERRIMAN D, GALLWEY JD. Clinical assessment of body hair growth in women. J Clin Endocrinol Metab. 1961; 21: 1440–1447.
- Faul F, Erdfelder E, Buchner A, et al. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009; 41(4): 1149–1160.
- Kali A, Shetty KS. Endocan: a novel circulating proteoglycan. Indian J Pharmacol. 2014; 46(6): 579–583.
- Balta I, Balta S, Koryurek OM, et al. Serum endocan levels as a marker of disease activity in patients with Behçet disease. J Am Acad Dermatol. 2014; 70(2): 291–296.
- Saldir M, Tunc T, Cekmez F, et al. Endocan and Soluble Triggering Receptor Expressed on Myeloid Cells-1 as Novel Markers for Neonatal Sepsis. Pediatr Neonatol. 2015; 56(6): 415–421.
- Celık T, Balta S, Karaman M, et al. Endocan, a novel marker of endothelial dysfunction in patients with essential hypertension: comparative effects of amlodipine and valsartan. Blood Press. 2015; 24(1): 55–60.
- Zuwala-Jagiello J, Simon K, Kukla M, et al. Increased circulating endocan in patients with cirrhosis: relation to bacterial infection and severity of disease. J Physiol Pharmacol. 2017; 68(2): 273–282.
- Laloglu E, Kumtepe Y, Aksoy H, et al. Serum endocan levels in endometrial and ovarian cancers. J Clin Lab Anal. 2017; 31(5).
- Schuitemaker JHN, Cremers TI, Van Pampus MG, et al. Changes in endothelial cell specific molecule 1 plasma levels during preeclamptic pregnancies compared to healthy pregnancies. Pregnancy Hypertens. 2018; 12: 58–64.
- Samy N, Hashim M, Sayed M, et al. Clinical significance of inflammatory markers in polycystic ovary syndrome: their relationship to insulin resistance and body mass index. Dis Markers. 2009; 26(4): 163–170.
- Sarrazin S, Adam E, Lyon M, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta. 2006; 1765(1): 25–37.
- Lee W, Ku SK, Kim SW, et al. Endocan elicits severe vascular inflammatory responses in vitro and in vivo. J Cell Physiol. 2014; 229(5): 620–630.
- Zafari Zangeneh F, Naghizadeh MM, Masoumi M. Polycystic ovary syndrome and circulating inflammatory markers. Int J Reprod Biomed (Yazd). 2017; 15(6): 375–382.
- Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011; 95(3): 1048–10458.e1.
- Rajendran S, Willoughby SR, Chan WP, et al. Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis. 2009; 204(2): 509–514.
- Repaci A, Gambineri A, Pasquali R. The role of low-grade inflammation in the polycystic ovary syndrome. Mol Cell Endocrinol. 2011; 335(1): 30–41.
- Balta S, Mikhailidis DP, Demirkol S, et al. Endocan: A novel inflammatory indicator in cardiovascular disease? Atherosclerosis. 2015; 243(1): 339–343.
- Cox LAE, van Eijk LT, Ramakers BPC, et al. Inflammation-induced increases in plasma endocan levels are associated with endothelial dysfunction in humans in vivo. Shock. 2015; 43(4): 322–326.
- Mohlig M, Spranger J, Osterhoff M, et al. The polycystic ovary syndrome per se is not associated with increased chronic inflammation. European Journal of Endocrinology. 2004; 150(4): 525–532.
- Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259(5091): 87–91.
